Investor Relations Press Releases February 20, 2026 Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates February 3, 2026 Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 December 19, 2025 BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook View all press releases » Events & Presentations Nov 18, 2025 at 4:30 PM GMT Jefferies 2025 Global Healthcare Conference London Listen to Webcast Nov 10, 2025 at 2:45 PM EST 2025 UBS Global Healthcare Conference Listen to Webcast Nov 4, 2025 at 8:30 AM EST Amicus Third Quarter 2025 Results Conference Call and Webcast Listen to Webcast View all events & presentations »
February 20, 2026 Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
February 3, 2026 Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
December 19, 2025 BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
Nov 4, 2025 at 8:30 AM EST Amicus Third Quarter 2025 Results Conference Call and Webcast Listen to Webcast